Código QR (código de barras bidimensional)

Physiologically-Based Pharmacokinetics of Ribociclib Drug–Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer

<b>Background:</b> Ribociclib, initially approved for HR+/HER2− advanced breast cancer (ABC) at a 600 mg dose, was recently approved for HR+/HER2− early breast cancer (EBC) at a 400 mg dose based on the NATALEE trial. Differences in dose and patient population warrant reassessment of ribociclib drug...

תיאור מלא

שמור ב:
Principais autores: Yan Ji, Felix Huth, Craig Wang, Hilmar Schiller, Francois Pierre Combes, John Crown, Peter A. Fasching, Juan Pablo Zarate, Michael Untch
פורמט: Artigo
שפה:Inglês
יצא לאור: MDPI AG 2026-03-01
סדרה:Pharmaceuticals
נושאים:
drug–drug interaction
early breast cancer
ribociclib
hepatic impairment
renal impairment
CYP3A4
גישה מקוונת:https://www.mdpi.com/1424-8247/19/3/461
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים